Modality
Radioligand
MOA
EGFRi
Target
BET
Pathway
Ferroptosis
PSPCML
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Aug 2028
ApprovedCurrent
NCT03518582
2,679 pts·CML
2024-04→2028-08·Not yet recruiting
NCT08319372
1,815 pts·PSP
2025-12→2028-05·Terminated
NCT08327401
2,466 pts·CML
2017-06→TBD·Recruiting
+1 more trial
8,122 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2026-08-094mo awayPh3 Readout· CML
2028-05-172.1y awayPh3 Readout· PSP
2028-08-242.4y awayPh3 Readout· CML
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Recruit…
Approved
Complet…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2026-08-09 · 4mo away
CML
Ph3 Readout
2028-05-17 · 2.1y away
PSP
Ph3 Readout
2028-08-24 · 2.4y away
CML
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03518582 | Approved | CML | Not yet recr... | 2679 | 6MWD |
| NCT08319372 | Approved | PSP | Terminated | 1815 | EASI-75 |
| NCT08327401 | Approved | CML | Recruiting | 2466 | EASI-75 |
| NCT08287403 | Approved | CML | Completed | 1162 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET |